Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P 

Saved in:
Bibliographic Details
Published in:Cancer 2016-12, Vol.122 (24), p.3856-3864
Main Authors: Sherman, Steven I., Clary, Douglas O., Elisei, Rossella, Schlumberger, Martin J., Cohen, Ezra E. W., Schöffski, Patrick, Wirth, Lori J., Mangeshkar, Milan, Aftab, Dana T., Brose, Marcia S.
Format: Article
Language:English
Subjects:
Anilides - therapeutic use
cabozantinib
Disease-Free Survival
Double-Blind Method
Humans
medullary thyroid cancer
Mutation - genetics
Proto-Oncogene Proteins c-ret - genetics
Pyridines - therapeutic use
RAS
ras Proteins - genetics
RET
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - genetics
Thyroid Neoplasms - pathology
tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Cabozantinib significantly prolonged progression‐free survival (PFS) versus a placebo in patients with progressive, metastatic medullary thyroid cancer (MTC; P 
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.30252